Contemporary Practices for Management of Subclinical Atrial Fibrillation.

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Subclinical atrial fibrillation (SCAF) is common in patients with cardiac implantable electronic devices (CIEDs).
• SCAF episodes may precede clinical atrial fibrillation and increase thromboembolic event risk.
• Management strategies for SCAF, particularly oral anticoagulation (OAC) use, are not well-established and remain controversial.

Purpose of the Study:

• To review current literature and clinical studies on SCAF management.
• To guide decision-making regarding anticoagulation therapy for SCAF.
• To identify treatment options to limit complications in patients with SCAF.

Main Methods:

• Comprehensive literature review using Medline, Scopus, Google Scholar, and Embase databases.
• Analysis of current literature and clinical studies pertaining to SCAF and atrial high-rate episodes (AHREs).
• Focus on evidence guiding anticoagulation and complication-limiting strategies.

Main Results:

• The decision to initiate OAC for SCAF/AHREs should be individualized.
• Risk-benefit assessment balancing stroke risk against bleeding potential is crucial.
• Optimal patient subgroups benefiting from OAC require further clarification.

Conclusions:

• Individualized assessment is paramount for OAC decisions in SCAF/AHREs.
• Ongoing research is necessary to refine treatment guidelines for SCAF.
• Future studies will clarify which patient subgroups benefit most from anticoagulation therapy.